Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Susceptibility-weighted imaging and quantitative susceptibility mapping in the brain.
A preliminary study of functional imaging upon placebo analgesia in progressive multiple sclerosis.
Association of IL-13 single nucleotide polymorphisms in Iranian patients to multiple sclerosis.
Depressive state and chronic fatigue in multiple sclerosis and neuromyelitis optica.
Role of neuroinflammation in neurodegenerative diseases (Review).
Forceps minor damage and co-occurrence of depression and fatigue in multiple sclerosis.
Site-Specific Chemokine Expression Regulates Central Nervous System Inflammation and Determines Clinical Phenotype in Autoimmune Encephalomyelitis.
A report from the American Academy of Neurology 2014 Annual Meeting (April 26-May 3 - Philadelphia, Pennsylvania, USA).
Repeat infusion of autologous bone marrow cells in multiple sclerosis: protocol for a phase I extension study (SIAMMS-II).
Higher expression of IL-12Rβ2 is associated with lower risk of relapse in relapsing-remitting multiple sclerosis patients on interferon-β1b therapy during 3-year follow-up.
Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses.
Development and validation of an ELISA for quantification of soluble IFN-β receptor: assessment in multiple sclerosis.
Mapping search terms to review goals is essential.
Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis.
Extracellular Membrane Vesicles as Vehicles for Brain Cell-to-Cell Interactions in Physiological as well as Pathological Conditions.
Outcomes of Cognitive-Behavioral Treatment for Insomnia on Insomnia, Depression, and Fatigue for Individuals with Multiple Sclerosis: A Case Series.
Specificities of children with multiple sclerosis and neuromyelitis optica.
A Quality-Adjusted Life-Year Measure for Multiple Sclerosis: Developing a Patient-Reported Health State Classification System for a Multiple Sclerosis-Specific Preference-Based Measure.
Use of the VH6-1 gene segment to code for anti-interleukin-18 autoantibodies in multiple sclerosis.
Quantitative analysis of cerebrospinal fluid brain derived neurotrophic factor in the patients with multiple sclerosis.
EphA4 Receptor Tyrosine Kinase Is a Modulator of Onset and Disease Severity of Experimental Autoimmune Encephalomyelitis (EAE).
Next-Generation Sequencing Identifies MicroRNAs that Associate with Pathogenic Autoimmune Neuroinflammation in Rats.
The magnetic resonance imaging 'rule of five': predicting the occurrence of relapse.
Blinded and unblinded internal pilot study designs for clinical trials with count data.
The proline-rich region of 18.5-kDa myelin basic protein binds to the SH3-domain of Fyn tyrosine kinase with the aid of an upstream segment to form a dynamic complex in vitro.
Pages
« first
‹ previous
…
653
654
655
656
657
658
659
660
661
…
next ›
last »